1. Generics Bulletin
  3. >>Generics

US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs

 
• By Derrick Gingery

Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.

FY13-FY17 Linkage of Research To Pre-ANDA Meetings
In some generic product categories where there were many FDA research projects, there also were several pre-ANDA meeting requests, suggesting the studies may have helped sponsors move forward with development. • Source: FDA presentation slides

It appears the US FDA may be able to influence generic drug sponsors' development priorities with its research projects, or at least pique their interest.

Data suggests that pre-ANDA meeting requests sometimes correlate with the number of internal and external research projects in the category,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By Dave Wallace

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By Dean Rudge

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

IGBA Asks G7 To Consider Access Issues

 
• By Dave Wallace

The International Generic and Biosimilar medicines Association has set out three priority areas that it says should be considered by G7 leaders at the current summit in Alberta, Canada, as part of efforts towards ensuring access to health.